Last reviewed · How we verify
AMT-253
At a glance
| Generic name | AMT-253 |
|---|---|
| Sponsor | Multitude Therapeutics (Australia) Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AMT-253 in Patients With Advanced Solid Tumours (PHASE1, PHASE2)
- AMT-253 in Patients With Selected Advanced Solid Tumours (PHASE1)
- Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMT-253 CI brief — competitive landscape report
- AMT-253 updates RSS · CI watch RSS
- Multitude Therapeutics (Australia) Pty Ltd portfolio CI